Broad Neutralization of Staphylococcus aureus by AZD7745 Targeting ClfA

Overview

AZD7745, a monoclonal antibody targeting the ClfA adhesin of Staphylococcus aureus, demonstrates broad neutralizing activity across diverse global clinical isolates. Structural analysis revealed that AZD7745 binds a conserved epitope on the ClfA N3 domain, inducing conformational changes that inhibit fibrinogen binding, a key step in bacterial adherence and immune evasion.

Background

Staphylococcus aureus is a leading cause of bloodstream infections with high morbidity and mortality worldwide. Clumping factor A (ClfA) is a fibrinogen-binding surface protein critical for bacterial adherence and immune evasion, making it a promising target for therapeutic antibodies. Previous clinical trials targeting ClfA have failed to show efficacy, likely due to antigenic variability. AZD7745 is a human monoclonal antibody developed to neutralize multiple ClfA variants, potentially overcoming these limitations.

Data Highlights

Key Findings

• AZD7745 binds a conserved epitope comprising 12 residues on the ClfA N3 domain.
• Despite amino acid variations in 29 ClfA subtypes, AZD7745 neutralized all tested variants in vitro.
• Binding of AZD7745 induces a conformational change in ClfA that prevents fibrinogen interaction.
• The clfA gene is universally present in global S. aureus bloodstream isolates, supporting broad applicability.
• Combination therapy with AZD7745 and anti-alpha toxin antibody suvratoxumab provides broad strain coverage in preclinical models.

Clinical Implications

AZD7745 represents a promising immunotherapeutic candidate for preventing or treating S. aureus bloodstream infections by targeting a conserved functional epitope on ClfA. Its broad neutralizing activity across diverse clinical isolates suggests potential utility as an adjunct to antibiotic therapy, especially in cases involving device-associated infections. Further clinical evaluation is warranted to confirm efficacy and safety in humans.

Conclusion

The structural and functional characterization of AZD7745 reveals a mechanism for broad neutralization of S. aureus via inhibition of ClfA-mediated fibrinogen binding. This supports the development of AZD7745 as a broadly effective monoclonal antibody therapy against S. aureus infections.

References

1. Original Article 2024 -- Elucidating the Structure of ClfA002 Bound to Neutralizing Antibody AZD7745